Xeris Biopharma Holdings, Inc. Stock Nasdaq
Equities
XERS
US98422L1070
Pharmaceuticals
Financials (USD)
Sales 2024 * | 187M | Sales 2025 * | 220M | Capitalization | 349M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -31M | EV / Sales 2024 * | 1.86 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.58 x |
P/E ratio 2024 * |
-5.86
x | P/E ratio 2025 * |
-11
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.31% |
Latest transcript on Xeris Biopharma Holdings, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Paul Edick
CEO | Chief Executive Officer | 68 | 21-04-30 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 21-09-30 |
John Shannon
PSD | President | 62 | 21-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
1st Jan change | Capi. | |
---|---|---|
+64.65% | 854B | |
+39.71% | 636B | |
-4.89% | 361B | |
+17.19% | 324B | |
+9.45% | 301B | |
+14.40% | 247B | |
+6.34% | 230B | |
+17.37% | 228B | |
+15.35% | 177B |